BNTX Quote, Financials, Valuation and Earnings

Edap TMS SA has a net margin of 15.91% compared to BioNTech SE's net margin of -48.85%. BioNTech SE's return on equity of -2.35% beat Edap TMS SA's return on equity of -42.5%.

BioNTech SE has a consensus price target of $137.54, signalling upside risk potential of 21.63%. On the other hand Edap TMS SA has an analysts' consensus of -- which suggests that it could grow by 384.85%. Given that Edap TMS SA has higher upside potential than BioNTech SE, analysts believe Edap TMS SA is more attractive than BioNTech SE.

BioNTech SE has a beta of 0.217, which suggesting that the stock is 78.349% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.329, suggesting its less volatile than the S&P 500 by 67.134%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.4B, which are larger than Edap TMS SA quarterly revenues of $14.4M. BioNTech SE's net income of $217.9M is higher than Edap TMS SA's net income of -$7M. Notably, BioNTech SE's price-to-earnings ratio is 184.86x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.26x versus 1.19x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 15.91% compared to BioNTech SE's net margin of 0.7%. BioNTech SE's return on equity of -2.35% beat Moderna's return on equity of -17.44%.

BioNTech SE has a consensus price target of $137.54, signalling upside risk potential of 21.63%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 88.34%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

BioNTech SE has a beta of 0.217, which suggesting that the stock is 78.349% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.4B, which are smaller than Moderna quarterly revenues of $1.9B. BioNTech SE's net income of $217.9M is higher than Moderna's net income of $13M. Notably, BioNTech SE's price-to-earnings ratio is 184.86x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.26x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 15.91% compared to BioNTech SE's net margin of 25.23%. BioNTech SE's return on equity of -2.35% beat Pfizer's return on equity of 4.63%.

BioNTech SE has a consensus price target of $137.54, signalling upside risk potential of 21.63%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that BioNTech SE has higher upside potential than Pfizer, analysts believe BioNTech SE is more attractive than Pfizer.

BioNTech SE has a beta of 0.217, which suggesting that the stock is 78.349% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. BioNTech SE pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.4B, which are smaller than Pfizer quarterly revenues of $17.7B. BioNTech SE's net income of $217.9M is lower than Pfizer's net income of $4.5B. Notably, BioNTech SE's price-to-earnings ratio is 184.86x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.26x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of 15.91% compared to BioNTech SE's net margin of -31.41%. BioNTech SE's return on equity of -2.35% beat Trinity Biotech PLC's return on equity of --.

BioNTech SE has a consensus price target of $137.54, signalling upside risk potential of 21.63%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1775%. Given that Trinity Biotech PLC has higher upside potential than BioNTech SE, analysts believe Trinity Biotech PLC is more attractive than BioNTech SE.

BioNTech SE has a beta of 0.217, which suggesting that the stock is 78.349% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.133%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.4B, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. BioNTech SE's net income of $217.9M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, BioNTech SE's price-to-earnings ratio is 184.86x while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.26x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.